Post-earnings recap
Reported
Mon, Aug 10, 2026
EPS actual
$-0.78
EPS est.
$-0.64
EPS surprise
-21.12%
1-day move
+0.22%
BridgeBio Pharma's earnings report shows significant revenue growth, primarily driven by strong sales of Attruby. Although the company missed EPS expectations, the stock reacted positively, likely due to the impressive revenue increase and the potential for Attruby's future success. The upcoming regulatory reviews for three late-stage programs could also contribute to investor optimism.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.78 | $-0.57 | -21.12% |
| Revenue | $243.7M | $220M | +10.8% |
| Attruby Sales | $222.4M | N/A | N/A |
Management expressed cautious optimism about Attruby's performance and its potential to become a blockbuster. They highlighted the progress of late-stage programs and the improvement in operating loss.
Attruby is expected to reach blockbuster status in 2026.
Three late-stage programs have entered regulatory review.
BridgeBio Pharma, Inc. is a biotechnology company focused on developing therapies for genetic diseases. With a market cap of $16 billion, it operates in the health care sector, which is increasingly important as advancements in biotechnology continue to shape treatment options for patients.
Last quarter
In Q1-2026, BridgeBio reported an EPS of $-0.84, which was worse than the expected $-0.70, leading to a negative surprise. The stock reacted by declining 0.94% the following day.
EPS beat streak
0Q
EPS beat rate
25%
Avg EPS surprise
-13.74%
Avg 1-day reaction
+0.42%
Analysts expect BridgeBio to report a loss of $-0.57 per share on $220 million in revenue. Given the company's recent performance, there is cautious optimism about whether it can meet these expectations.
Bull case
If BridgeBio can exceed revenue expectations, it could signal strong demand for its products and a potential turnaround in profitability, boosting investor confidence.
Bear case
A failure to meet earnings expectations could raise concerns about the company's financial health and ability to manage costs, leading to further stock declines.
Key metrics to watch
EPS
$-0.57Earnings per share is a key indicator of profitability and will show how well the company is managing its expenses relative to revenue.
Revenue
$220MRevenue figures provide insight into the company's sales performance and overall market demand for its products.
The print will turn on these.
Q1
Will BridgeBio's revenue meet or exceed the $220 million consensus estimate?
Meeting or exceeding revenue expectations could indicate strong market demand for its therapies, which is crucial for investor confidence.
Q2
How does management plan to address the recent trend of EPS misses?
Investors will closely watch for any strategic plans to improve profitability, as consistent misses could raise concerns about the company's financial stability.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±18.2%
Why consensus could be wrong
The consensus may underestimate the potential for BridgeBio to surprise on revenue, given recent positive developments in its pipeline that have not been fully factored into estimates.
Supporting evidence
The options market is pricing a smaller move than the historical average, suggesting a potential undervaluation of the stock's volatility.
The recent trend of EPS surprises indicates that the company has the potential to exceed expectations despite recent misses.
Key risk
If revenue comes in significantly above $220 million, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
This quarter's performance is critical as it follows a pattern of EPS misses, and investors are looking for signs of recovery or further decline.
Bull confirmed if
Revenue exceeding $220 million would confirm strong market demand and could lead to a positive reassessment of the company's growth potential.
Bear confirmed if
An EPS worse than the consensus of $-0.57 would raise serious concerns about the company's financial management and future prospects.
What the market is pricing for the move.
Implied Move
±1.75%
Historical Avg
±2.17%
The options market is pricing in a modest move around the earnings report, suggesting that investors are uncertain about the outcome.
Options are pricing a smaller move than the historical average, indicating a potentially undervalued setup.
ATM IV
0.5%
30d HV
41.9%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing cheap setup in Health Care
Fade rate: 13 of 29 (45%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.8%, with a raw directional average of -1.4% (modestly negative historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
99.57%
of float
Insider
3.91%
of float
Holders
646
institutions
Top Holders· as of Jun 2026
Jupiter Topco LLC
14,110,278 sh · $938.3M
7.22%
100.0%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If BridgeBio beats expectations, history suggests a potential stock increase of around 1.48%, confirming a positive outlook for the company.
In line / cautious
If results are in line with expectations, the stock may react cautiously, reflecting uncertainty about future growth.
Miss
If the company misses expectations, history suggests a potential decline of about 1.48%, which could lead to increased skepticism about its financial health.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
1
1 buy·0 sells
Members
1
House only
Est. Notional
$1,001.00–$15,000.00
disclosed dollar ranges
Most Active Members
1 trade
The lines on the call that would change the story.
Kohlberg Kravis Roberts & Co. L.P.
13,260,971 sh · $881.9M
6.78%
Flat
Farallon Capital Management LLC
10,743,063 sh · $714.4M
5.50%
14.7%
Blackrock Inc.
10,287,156 sh · $684.1M
5.26%
-27.6%
Viking Global Investors, L.P.
9,949,219 sh · $661.6M
5.09%
-16.0%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net buying
Recent Transactions
Traded May 11, 2026 · disclosed Jun 8, 2026
$1,001.00–$15,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.